Melanoma (Issue 5) | Special Reports

BRAF Testing Important for Clinical Decision-Making in Metastatic Melanoma

January 05, 2016

Clinical Articles

With the continuously expanding landscape of treatment options for advanced and/or metastatic melanoma, it is becoming increasingly important to understand the patient-specific oncogenic drivers as a means of selecting treatments.

Managing Toxicities in Targeted Therapies for Metastatic Melanoma

November 03, 2015

Clinical Articles

Although single-target inhibitors and have demonstrated significant clinical benefit, the toxicities are not limited to cancer cells alone and associated toxicities and adverse events are often observed.

New Tumor Suppressor Gene in Melanoma Discovered

November 02, 2015

Clinical Articles

The Weizmann Institute of Science recently revealed a new gene belonging to the tumor suppressor gene group, RASA2, which is driving a particular deadly subset of melanomas for patients with dysfunctioning RAS pathways.

Increasing Immunotherapy Responses Possible With Selective Epigenetic Reprogramming

October 30, 2015

Clinical Articles

A paper recently published online by a group at the University of Michigan details a mechanism by which epigenetic modulation can increase the number of tumor infiltrating CD8+ T cells and could potentially lead to increased immunotherapy response.